State Street SPDR S&P Biotech ETF
274 hedge funds and large institutions have $2.17B invested in State Street SPDR S&P Biotech ETF in 2016 Q4 according to their latest regulatory filings, with 82 funds opening new positions, 76 increasing their positions, 72 reducing their positions, and 28 closing their positions.
193% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 28
88.91% more ownership
Funds ownership: 0% → 88.91% (+89%)
20% more funds holding
Funds holding: 228 → 274 (+46)
6% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 72
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
28% less call options, than puts
Call options by funds: $793M | Put options by funds: $1.1B
58% less capital inflows, than outflows
Capital inflows: $474M | Capital outflows: $1.12B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$75.5M |
| 2 |
VF
Virtu Financial
New York
|
+$33.9M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$31.2M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$31M |
| 5 |
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$27.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$275M |
| 2 |
Goldman Sachs
New York
|
-$258M |
| 3 |
Discovery Capital Management
South Norwalk,
Connecticut
|
-$99.4M |
| 4 |
Credit Suisse
Zurich,
Switzerland
|
-$95.3M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$92.9M |
XBI Hedge Fund Activity: Q4 2016 in Review
274 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2016, worth a combined $2.17B — down 30% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new XBI positions and 28 closed out — a net gain of 54 holders — while 76 added to existing stakes and 72 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $75.5M. The largest seller was Citigroup, cutting an estimated $275M.
- 274 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2016, up from 228 in Q3 2016.
- Funds reported $2.17B of State Street SPDR S&P Biotech ETF stock for Q4 2016, down 30% quarter-over-quarter.
- 82 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2016 and 28 closed out, a net change of +54 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2016 was Suvretta Capital Management, an estimated $75.5M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2016 was Citigroup, an estimated $275M sold.
Based on aggregated 13F filings for Q4 2016.